Lipidomics and proteomics in MASLD: reading the molecular script toward precision therapeutics

Area of Science:

• Hepatology and Metabolic Disorders
• Molecular Biology
• Biochemistry

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing multisystemic condition.
• MASLD involves intricate metabolic, inflammatory, and fibrogenic processes.
• Understanding MASLD's molecular underpinnings is crucial for effective treatment.

Purpose of the Study:

• To explore the roles of lipidomics and proteomics in MASLD pathophysiology.
• To identify molecular signatures that drive MASLD initiation and progression.
• To assess the potential of integrating multi-omics data for therapeutic advancements.

Main Methods:

• Utilized advanced lipidomic and proteomic analyses.
• Investigated qualitative lipid alterations and protein signaling networks.
• Reviewed emerging translational evidence on pharmacological interventions.

Main Results:

• Identified bioactive lipids (e.g., ceramides, free cholesterol) contributing to lipotoxicity and inflammation.
• Discovered proteomic pathways linked to cellular senescence and hepatic stellate cell activation.
• Observed that pharmacological agents may impact MASLD molecular signatures.

Conclusions:

• Lipidomics and proteomics offer deep insights into MASLD pathogenesis.
• Integrating these molecular data can enhance disease stratification and biomarker discovery.
• This approach supports the development of mechanism-based therapies for precision medicine in MASLD.